Catalyst Pharmaceuticals Inc. (CPRX) has reported encouraging results from an investigator-sponsored trial evaluating its investigational drug candidate Firdapse as a treatment for myasthenia gravis patients with anti-MuSK antibodies.
from RTT - Biotech http://ift.tt/2naggCg
via IFTTT
No comments:
Post a Comment